Report : North America Overactive Bladder Treatment Market Forecast to 2028 – COVID-19 Impact and Regional Analysis – by Pharmacotherapy (Anticholinergics, Mirabegron, Botox, Neurostimulation, and Intravesical Instillation) and Disease Type (Idiopathic Overactive Bladder and Neurogenic Bladder)
At 3.4% CAGR, the North America Overactive Bladder Treatment Market is speculated to be worth US$ 2,059.43 Million by 2028, says Business Market Insights
According to Business Market Insights’ research, the North America overactive bladder treatment market was valued at US$ 1,682.29 million in 2022 and is expected to reach US$ 2,059.43 million by 2028, registering a CAGR of 3.4% from 2022 to 2028. Increase in prevalence of urinary incontinence and growing incidence of urinary tract infections are the critical factors attributed to the North America overactive bladder treatment market expansion.
Urinary tract infection (UTI) may lead to increased activity in the bladder wall muscles, causing symptoms similar to an overactive bladder. The bacteria causing UTIs reside in the lining of urothelial cells and they attack the host body when their innate immunity is low. Individuals with recurrent UTIs are found to have voiding dysfunction and detrusor overactivity, and these functional abnormalities may further damage the integrity of the urothelial barrier. A study conducted by a group of researchers at the American College of Physicians and Infectious Diseases Society of America in 2020 states UTIs are the cause of ~6 million physician visits each year in the US. In Canada, ~500,000 visits to the doctor’s office are for UTI consultations every year. UTI is the eighth and fifth most common reason for ambulatory clinic visits and emergency department visits, respectively, in the country. Thus, the increasing prevalence of UTIs, coupled with the association of UTIs with overactive bladder, is one of the prominent factors contributing to the North America overactive bladder treatment market growth.
On the contrary, recalls of therapeutic drugs hurdles the growth of North America overactive bladder treatment market.
Based on pharmacotherapy, the North America overactive bladder treatment market is segmented into anticholinergics, mirabegron, botox, neurostimulation, and intravesical instillation. The mirabegron segment held 39.5% market share in 2022, amassing US$ 663.75 million. It is projected to garner US$ 795.00 million by 2028 to expand at 3.7% CAGR during 2022–2028.
Based on disease type, the North America overactive bladder treatment market is bifurcated into idiopathic overactive bladder and neurogenic bladder. The idiopathic overactive bladder segment held 61.7% market share in 2022, amassing US$ 1,037.88 million. It is projected to garner US$ 1,292.66 million by 2028 to expand at 3.7% CAGR during 2022–2028.
Based on country, the North America overactive bladder treatment market is segmented into the US, Canada, and Mexico. Our regional analysis states that the US captured 66.5% market share in 2022. It was assessed at US$ 1,117.88 million in 2022 and is likely to hit US$ 1,395.26 million by 2028, exhibiting a CAGR of 3.8% during the forecast period.
Key players dominating the North America overactive bladder treatment market are AbbVie Inc; Alembic Pharmaceuticals Limited; Astellas Pharma Inc; Axonics Modulation Technologies, Inc; Colorado Urology Associates, PLLC; Endo Pharmaceuticals Inc.; Hisamitsu Pharmaceutical Co., Inc.; Medtronic Plc; Pfizer Inc; and Teva Pharmaceutical Industries Ltd, among others.
- In Feb 2022, InterStim systems are the standard of care in advanced therapy options, and the most personalized system, to deliver sacral neuromodulation (SNM) therapy.
- In 2021, Solifenacin Succinate Tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency, and urinary frequency.
Contact Person: Sameer Joshi
Phone: +1- 646- 491- 9876
Email id: firstname.lastname@example.org